We review our content at regular intervals and update it whenever new research or a change in clinical guidelines requires it.
| FIELD OF APPLICATION | DETAILS |
|---|---|
| Generic Name | Dihydroergocornine |
| Active Ingredient | Dihydroergocornine mesylate |
| Brand Names | Ergoloid Mesylates |
| Drug Category | Neurology |
| Drug Class | Palliative treatment, Immunosuppressive therapy, Targeted therapy |
| Dosage Forms | Tablet, Tablet, orally disintegrating |
| Route of Administration | Oral |
| FDA Approval Status | Not approved |
Dihydroergocornine: Overview
Dihydroergocornine is an artificial, hydrogenated derivative of ergocornine, an ergot alkaloid extracted from Claviceps purpurea. It is chemically classified as an ergopeptine and functions as a central nervous system nootropic and cardiovascular agent. Historically, dihydroergocornine was used as an essential component of the co-dergocrin mesylate (ergoloid mesylates) combination product to manage age-related cognitive decline, dementia, and idiopathic declines in mental capacity among elderly individuals.
What Is Dihydroergocornine & How Does It Work?
Dihydroergocornine belongs to the class of organic compounds known as ergopeptines. These are complex ergoline derivatives containing a tripeptide structure attached to a basic ergoline ring. The chemical structure is formed by hydrogenating the double bonds in the lysergic acid ring of crude ergocornine.
The exact central mechanisms by which dihydroergocornine improves cognitive function remain incompletely defined. However, it exhibits complex central and peripheral neuropharmacological activity by acting as a partial agonist and antagonist at alpha-adrenergic, beta-adrenergic, serotonin, and dopamine receptors. It possesses potent sympathicolytic and adrenolytic properties. By stimulating central vasodilator centers and inhibiting stimulation-induced noradrenaline overflow, it exerts significant hypotensive effects. At higher concentrations, it also increases vascular smooth muscle tone, aiding cerebral blood flow regulation and neuronal metabolic function in aging brains.
Is Dihydroergocornine FDA Approved?
No, Dihydroergocornine as a single active ingredient is Not Approved by the U.S. Food and Drug Administration (FDA) for independent prescription use.
It is found as one of the components in the ergoloid mesylate mixture. While fixed-combination oral tablets containing dihydroergocornine were historically marketed in the United States, dihydroergocornine itself does not carry independent FDA approval or an active independent NDA.
What Is Dihydroergocornine Used For?
Dihydroergocornine was primarily utilized as a combined nootropic agent in elderly care prior to its market withdrawal.
- Idiopathic Mental Capacity Decline: Approved in combination formulations (Ergoloid Mesylates) for the symptomatic treatment of age-related cognitive decline, memory impairment, and idiopathic decreased mental activity in patients over sixty years of age
- Dementia & Cerebrovascular Insufficiency: Prescribed historically to improve cerebral metabolic efficiency, microcirculation, and mood stability in vascular dementia
Before Taking Dihydroergocornine: Contraindications & Precautions
Clinicians and patients must understand the physiological precautions and vascular risks associated with ergot derivatives. Proper screening helps avoid severe cardiovascular or ischemic events.
Who Should Not Take Dihydroergocornine?
Dihydroergocornine is contraindicated in individuals with known hypersensitivity to ergot alkaloids or mesylate salts. It must not be administered to patients with severe underlying hypotension, acute porphyria, severe hepatic impairment, or active peripheral vascular disease.
Dihydroergocornine: Pregnancy & Fertility
Dihydroergocornine is strictly contraindicated during pregnancy and breastfeeding. Ergot derivatives possess uterine stimulant properties that can trigger uterine contractions, decreased placental perfusion, and fetal distress. Because ergot compounds suppress prolactin secretion and pass into human milk, nursing mothers must avoid this drug.
Tell Your Doctor Before Taking Dihydroergocornine
Inform your physician if you have a history of severe bradycardia, coronary artery disease, peptic ulcer disease, or chronic kidney disease. Disclose all current medications, particularly antihypertensives, dopamine agonists, and strong Cytochrome P450 inhibitors.
Dihydroergocornine: Dosage & Administration
Clinical dosing protocols for dihydroergocornine were established around fixed-dose combination ergoloid mesylate tablets.
Standard Dihydroergocornine Dosing
In the historic ergoloid mesylates mixture, dihydroergocornine mesylate was formulated at a dosage of 0.333 mg per tablet alongside equal parts of co-active ergot derivatives. The typical adult oral dosage was 1 mg (one combination tablet) administered three times daily. Standardized standalone single-ingredient dosing protocols are not available.
How Dihydroergocornine Is Administered
Dihydroergocornine was administered orally via standard film-coated or sublingual/orally disintegrating tablets. Sublingual tablets were allowed to dissolve under the tongue without chewing or swallowing immediately.
Dihydroergocornine: Clinical Efficacy & Research
Historical clinical trials investigating ergoloid mesylates demonstrated modest improvements in self-care, emotional lability, and mental clarity among elderly patients suffering from mild-to-moderate dementia. Research confirmed its ability to act on cerebral neurotransmitter systems and improve oxygen utilization in neural tissues. However, contemporary neurology reviews highlighted that its cognitive benefits were limited and inconsistent when evaluated against modern cholinesterase inhibitors and NMDA receptor antagonists, leading to its eventual clinical obsolescence.
Dihydroergocornine: Side Effects & Safety Profile
This medication does not have an FDA Black Box Warning.
While generally tolerated at low doses, dihydroergocornine carries safety risks characteristic of the ergot alkaloid class.
Common Dihydroergocornine Side Effects
Common adverse effects include gastrointestinal distress, nausea, vomiting, sublingual irritation (with sublingual forms), nasal congestion, dizziness, and mild facial flushing.
Serious Dihydroergocornine Adverse Events
Serious adverse events associated with ergot-derived mesylates include severe orthostatic hypotension, marked bradycardia, retroperitoneal or pleural fibrosis, ergotism (severe peripheral ischemia), and acute cardiac arrhythmias.
Managing Dihydroergocornine Side Effects
Mild nausea can be managed by taking oral doses with meals. If severe postural dizziness or symptomatic hypotension occurs, patients should lie down immediately, and healthcare providers must re-evaluate dosage or discontinue therapy.
Dihydroergocornine: Interactions & What to Avoid
Dihydroergocornine features significant metabolic and vascular drug interaction profiles.
Dihydroergocornine: Interactions
Dihydroergocornine is metabolized in the liver as a substrate of the Cytochrome P-450 CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole, erythromycin, or clarithromycin) significantly increases plasma drug concentrations, elevating the risk of vasospasm and severe ergotism. Combining dihydroergocornine with antihypertensive medications can cause additive hypotensive reactions, while concurrent use with other ergot derivatives or vasoconstrictors increases the risk of systemic ischemia.
Dihydroergocornine: Food & Alcohol
Taking oral tablets with food minimizes stomach upset. Grapefruit juice should be avoided because it inhibits CYP3A4 metabolism. Alcohol consumption must be strictly avoided, as it compounds ergot-induced vasodilation, dizziness, and central nervous system depression.
Dihydroergocornine: Missed Dose, Overdose & Storage
Proper storage and adherence to historical safety guidelines prevented drug degradation and acute toxicity.
Missed Dose of Dihydroergocornine
Not applicable for active therapy, as the product is withdrawn. Historically, if a dose was missed, patients were advised to take it as soon as remembered unless it was near the time for the next dose, avoiding double doses.
Dihydroergocornine: Overdose & Emergency
Acute overdose causes severe hypotension, collapse, nausea, vomiting, confusion, severe bradycardia, and peripheral vasospasm leading to numbness and coldness in extremities. Emergency treatment requires immediate supportive care, gastric lavage, intravenous fluid resuscitation, pressor agents for severe hypotension, and peripheral vasodilators.
How to Store Dihydroergocornine
Historical combination tablets were stored at controlled room temperature between 20°C and 25°C (68°F to 77°F) in light-resistant, tightly closed containers away from heat and moisture.
Dihydroergocornine: Patient Management & Monitoring
Clinical management focused on tracking cardiovascular stability and neurological status during ergoloid mesylate therapy.
Tests Before Starting Dihydroergocornine
Prior to starting therapy, clinicians obtained baseline blood pressure readings, pulse rates, liver function panels, and comprehensive cognitive assessments.
Monitoring During Dihydroergocornine Treatment
Patients required routine monitoring of sitting and standing blood pressure to detect orthostatic hypotension. Long-term therapy mandated periodic checks for signs of fibrotic changes or peripheral vascular impairment.
Dihydroergocornine: Do’s and Don’ts
Do report sudden numbness, tingling, or coldness in the hands or feet to a physician immediately. Don’t consume alcohol or use unverified ergot preparations.
Frequently Asked Questions
What is Dihydroergocornine?
Dihydroergocornine is a dihydrogenated ergot alkaloid derivative used historically in mixtures to treat idiopathic declines in mental capacity.
Is Dihydroergocornine FDA approved?
No, Dihydroergocornine as a single active ingredient is Not Approved by the FDA. It is found as one of the components in the ergoloid mesylate mixture.
How does Dihydroergocornine affect blood pressure?
It exerts potent adrenolytic and sympathicolytic effects, stimulating central vasodilator centers to lower blood pressure.
Does Dihydroergocornine have an FDA Black Box Warning?
This medication does not have an FDA Black Box Warning.
What class of organic compounds does Dihydroergocornine belong to?
It belongs to the class of ergopeptines, which are complex ergoline derivatives containing a tripeptide structure attached to the basic ergoline ring.
What was the brand name of Dihydroergocornine in the United States?
It was marketed in the US in fixed-dose combination tablets under the brand name Ergoloid Mesylates.
What enzyme metabolizes Dihydroergocornine?
It is a substrate for the Cytochrome P-450 CYP3A4 enzyme system.
References
- DrugBank Online. Dihydroergocornine (DB11273).
- National Center for Biotechnology Information (NCBI). PubChem Compound Summary: Dihydroergocornine.
Legal Disclaimer
The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.
